Literature DB >> 25949491

Bilateral renal vein thrombosis due to inapparent polycythaemia.

Ram Rapur1, Swarnalatha Gudithi1, Krishna Prasad Adiraju2, Srinivasasan Vangipurapu Rangacharlu2, Dakshinamurty Kaligotla Venkata1.   

Abstract

Thromboses at unusual sites are characteristic of polycythaemia. We present a patient of bilateral renal vein thromboses due to polycythaemia that was inapparent. The diagnosis was confirmed by trilineage hyperplasia in bone marrow and JAK 2 V617F mutation in blood.

Entities:  

Keywords:  inapparent polycythaemia; renal vein thrombosis

Year:  2011        PMID: 25949491      PMCID: PMC4421442          DOI: 10.1093/ndtplus/sfr047

Source DB:  PubMed          Journal:  NDT Plus        ISSN: 1753-0784


Background

Thromboses at unusual sites are characteristic of polycythaemia. They include occlusion of the splenic, portal, hepatic and mesenteric veins. There were neither reports of renal vein thrombosis (RVT) due to polycythaemia in adults nor had the aetiology of RVT in adults [1] included polycythaemia as one of the causes.

Case report

A 28-year-old gentleman, non-smoker, teetotaller, non-diabetic and non-hypertensive, presented with the complaints of dysuria, haematuria of one episode and swelling of the left lower limb over 5 days. There was no history of fever, loin pain, oliguria, headache, weakness, pruritus, dizziness, visual disturbances, joint pains, chest pain or breathlessness. Systemic examination was unremarkable. The investigations were in the Table 1.
Table 1.

Investigationsa

Investigations (results in SI units)On the first visitAfter 1 month
Haemoglobin (g/L)125–127156
Haematocrit (%)38–4047
Leucocycte count (per mm3)10 100–13 00013 500
Platelet count (lakhs/mm3)5.31–5.54.8
Peripheral smearnot doneNormocytic normochromic RBCs
Serum creatinine (μmol/L)88.479.6
Serum proteins (g/L)7080
Serum albumin (g/L)3246
24-h urine protein (mg/day)525138
Urine examinationpH: 6.0; specific gravity: 1015; albumin: 1+; glucose: nil; ketones: absent; RBCS: 6–10/h.p.f.; WBC: 6–8/h.p.f.pH: 6.0; specific gravity: 1020; albumin: 1+ glucose: nil; ketones: absent; RBCS: 4–6/h.p.f.; WBC: 2/h.p.f.
Serum homocysteine [reference range: <15 μmol/L)]19not done
Thyroid-stimulating hormone (reference range: 1.3–3.0 nmol/L)2.6not done
Lactate dehydrogenase (reference range: 200–400 IU/L)558not done
ANANegativenot done
Anti-dsDNANegativenot done
Anticardiolipin antibodies, IgG, IgA, IgMNegativenot done
HbsAgNegativenot done
Anti-HCV antibodiesNegativenot done
HIVNon-reactivenot done
Doppler of venous system of lower limbsSub-acute thrombosis, right and left common iliac, external iliac, common femoral, superficial femoral, poplitaeal, anterior and posterior tibial veins.not done
Partial recanalization of inferior vena cava, both renal veins at hilum.
Bone marrow biopsynot doneTrilineage hyperplasia (Figure 1)
Serum erythropoietin (reference range: 3.7 to 31.5 mU/mL)not done6.30
JAK 2 V617F mutationnot doneDetected in blood by PCR
ABGnot donepH: 7.466; pCO2: 43.5 mmHg; PO2: 96.5 mmHg; HCO3: 30.9 mmol/L

PCR, polymerase chain reaction; ANA, Anti nuclear antibody; HCV, Hepatitis C virus; ABG, Arterial blood gas analysis; dsDNA, double stranded DNA.

Investigationsa PCR, polymerase chain reaction; ANA, Anti nuclear antibody; HCV, Hepatitis C virus; ABG, Arterial blood gas analysis; dsDNA, double stranded DNA. Bone marrow aspirate (400X) showing trilineage hyperplasia on Giemsa stain.

Discussion

Often patients with splanchnic vein thrombosis, as in this patient, have normal haemoglobin and haematocrit levels. This phenomenon is regarded as ‘inapparent polycythaemia vera’ (IPV) [2]. The concept of IPV is observed in two circumstances. The first one is in patients where increased plasma mass masks an increased red cell mass. This is observed in patients of portal hypertension secondary to suprahepatic or portal vein thrombosis [3, 4]. In the series of Valla et al [3], among the four patients with portal vein thrombosis and increased plasma volume, the maximum haemoglobin observed was 140 g/L. Gastrointestinal bleeding and/or an increase in portal vein hypertension often explain the apparent normal result of the blood count. The second one is in the event of a standard iron deficiency during polycythaemia vera (PV) and is partly explained by the high frequency of gastric ulcers and gastritis estimated at 20–30% [5]. Resulting iron deficiency can be accompanied by hypochromia and microcytosis and occasionally a substantial decrease in haemoglobin levels. In this situation, PV is not always easy to diagnose, especially in the absence of splenomegaly and leucocytosis. Thrombocytosis may be present but secondary to iron deficiency. Iron supplementation and treatment of the local cause of bleeding enable the diagnosis to be reestablished, for the increase in haematocrit and haemoglobin levels is abnormal and rapid. [5] The real frequency of IPV is not yet established; but in one series, its frequency was 18 of 103 patients (17%) [5]. The red cell mass measurement to diagnose IPV is required in patients of isolated and unexplained thrombocytosis, hyperleucocytosis, splenomegaly or splanchanic vein thrombosis. [5] But with the advent of the molecular tests for the JAK2V617F mutation, the diagnosis of IPV has been dramatically simplified [6]. Because JAK2V617F is myeloid neoplasm specific and not found in other causes of polycythaemia, it has lent itself to being a sensitive diagnostic marker for PV. However, in the context of myeloid neoplasms, JAK2V617F is not specific for PV and is found in ∼50% of patients with essential thrombocythemia (ET), primary myelofibrosis (PMF) or ‘refractory anaemia with ringed sideroblasts associated with marked thrombocytosis’ and at a lesser frequency in other myeloid neoplasms but not in lymphoid tumours. Therefore, mutation screening for JAK2V617F cannot be used to distinguish one myeloproliferative neoplasm from another, but it does complement histology in the diagnosis of both ET and PMF by excluding the possibility of reactive thrombocytosis or myelofibrosis [6].
  6 in total

Review 1.  Polycythemia vera: myths, mechanisms, and management.

Authors:  Jerry L Spivak
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

2.  Inapparent polycythemia vera: an unrecognized diagnosis.

Authors:  T Lamy; A Devillers; M Bernard; A Moisan; I Grulois; B Drenou; L Amiot; R Fauchet; P Y Le Prise
Journal:  Am J Med       Date:  1997-01       Impact factor: 4.965

Review 3.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

4.  Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders.

Authors:  D Valla; N Casadevall; M G Huisse; M Tulliez; J D Grange; O Muller; T Binda; B Varet; B Rueff; J P Benhamou
Journal:  Gastroenterology       Date:  1988-04       Impact factor: 22.682

5.  Polycythaemia and portal vein thrombosis.

Authors:  B Drénou; P Y Le Prisé; B Poilane; I Bernard-Griffiths; C Ghandour; R Fauchet
Journal:  Nouv Rev Fr Hematol       Date:  1992

Review 6.  Renal vein thrombosis.

Authors:  M Asghar; K Ahmed; S S Shah; M K Siddique; P Dasgupta; M S Khan
Journal:  Eur J Vasc Endovasc Surg       Date:  2007-06-01       Impact factor: 7.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.